Literature DB >> 10574377

Caspase inhibition protects nigral neurons against 6-OHDA-induced retrograde degeneration.

B Cutillas1, M Espejo, J Gil, I Ferrer, S Ambrosio.   

Abstract

6-Hydroxydopamine (6-OHDA) administered intrastriatally to adult rats in a single injection causes neurodegeneration of the nigrostriatal pathway and loss of > 50% of dopamine neurons in substantia nigra pars compacta 30 days after administration. The death of nigral neurons occurs, at least partially, by a caspase-mediated mechanism. The nigral loss of dopaminergic neurons could be prevented by stereotaxical administration of zVAD.fmk, a caspase inhibitor, into the substantia nigra, indicating that 6-OHDA-induced nigrostriatal degeneration involves caspase activation. These results suggest that caspases are probably involved in neurodegenerative chronic processes such as Parkinson's disease and might be considered as possible targets in the treatment of such neurological disorders.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10574377     DOI: 10.1097/00001756-199908200-00030

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  10 in total

1.  Time-course of brain oxidative damage caused by intrastriatal administration of 6-hydroxydopamine in a rat model of Parkinson's disease.

Authors:  Sofía Sánchez-Iglesias; Pablo Rey; Estefanía Méndez-Alvarez; José Luis Labandeira-García; Ramón Soto-Otero
Journal:  Neurochem Res       Date:  2006-12-12       Impact factor: 3.996

2.  Intranigral dopamine toxicity and alpha-synuclein response in rats.

Authors:  Cristina Gómez-Santos; Pol Giménez-Xavier; Isidre Ferrer; Santiago Ambrosio
Journal:  Neurochem Res       Date:  2006-06-28       Impact factor: 3.996

3.  Involvement of the mitochondrial apoptotic pathway and nitric oxide synthase in dopaminergic neuronal death induced by 6-hydroxydopamine and lipopolysaccharide.

Authors:  Sarika Singh; Sachin Kumar; Madhu Dikshit
Journal:  Redox Rep       Date:  2010       Impact factor: 4.412

4.  Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro.

Authors:  Sang R Kim; Da Y Lee; Eun S Chung; Uh T Oh; Seung U Kim; Byung K Jin
Journal:  J Neurosci       Date:  2005-01-19       Impact factor: 6.167

5.  Caspase signalling controls microglia activation and neurotoxicity.

Authors:  Miguel A Burguillos; Tomas Deierborg; Edel Kavanagh; Annette Persson; Nabil Hajji; Albert Garcia-Quintanilla; Josefina Cano; Patrik Brundin; Elisabet Englund; Jose L Venero; Bertrand Joseph
Journal:  Nature       Date:  2011-03-09       Impact factor: 49.962

Review 6.  Role of nitric oxide synthases in Parkinson's disease: a review on the antioxidant and anti-inflammatory activity of polyphenols.

Authors:  Katia Aquilano; Sara Baldelli; Giuseppe Rotilio; Maria Rosa Ciriolo
Journal:  Neurochem Res       Date:  2008-04-16       Impact factor: 3.996

7.  Time course of deficits in open field behavior after unilateral neostriatal 6-hydroxydopamine lesions.

Authors:  Jaime Fornaguera; Rainer K W Schwarting
Journal:  Neurotox Res       Date:  2002-02       Impact factor: 3.911

8.  The carbonic anhydrase inhibitor methazolamide prevents amyloid beta-induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain.

Authors:  Silvia Fossati; Patrizia Giannoni; Maria E Solesio; Sarah L Cocklin; Erwin Cabrera; Jorge Ghiso; Agueda Rostagno
Journal:  Neurobiol Dis       Date:  2015-11-12       Impact factor: 5.996

9.  Dissociation of progressive dopaminergic neuronal death and behavioral impairments by Bax deletion in a mouse model of Parkinson's diseases.

Authors:  Tae Woo Kim; Younghye Moon; Kyungjin Kim; Jeong Eun Lee; Hyun Chul Koh; Im Joo Rhyu; Hyun Kim; Woong Sun
Journal:  PLoS One       Date:  2011-10-17       Impact factor: 3.240

10.  Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.

Authors:  Alexander Harkavyi; Amjad Abuirmeileh; Rebecca Lever; Ann E Kingsbury; Christopher S Biggs; Peter S Whitton
Journal:  J Neuroinflammation       Date:  2008-05-21       Impact factor: 8.322

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.